Naringin prevents the impairment of hepatic mitochondrial function in diabetic rats
Canadian Journal of Physiology and Pharmacology · 2025
DOI: 10.1139/cjpp-2024-0357 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2025. Verfasst von María A Rizzi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio "Dr. Fernando Cañas",Cátedra de Bioquímica y Biología Molecular, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, …. Hauptthemen laut MEDLINE: Flavanones, Diabetes Mellitus, Experimental, Mitochondria, Liver. Die Arbeit nennt 46 Literaturangaben. Gefördert von: FONCYT, SECYT-UNC (VAR), Argentina.
Abstract (Originalsprache)
We previously demonstrated that naringin (NAR) protects against liver damage in streptozotocin (STZ)-induced diabetes in rats. The aim of this study was to elucidate whether NAR is also able to protect the functioning, biogenesis and dynamics of the liver mitochondria in diabetic rats (DM). The activities of isocitrate dehydrogenase and malate dehydrogenase from the Krebs cycle, complex I–III from electron chain and adenosine triphosphate synthase were decreased in DM rats, effects that were blocked by NAR. The gene expression of mitofusin-2 and GTPase dynamin-related protein 1, markers of mitochondrial fusion and fission, were decreased in DM rats, which was prevented by NAR. Total glutathione was decreased and protein carbonyl contents as well as the activity of the antioxidant enzymes were increased in DM rats. All these changes were blocked by NAR. In conclusion, NAR protects the liver mitochondria from DM rats avoiding changes in the activity of Krebs cycle, the respiratory chain and the oxidative phosphorylation as well as preventing alterations in the fusion-fission processes. These effects are mediated, at least in part, by decreasing oxidative stress and anomalies in the enzymatic antioxidant system. Further studies are necessary to validate efficacy and safety of NAR for human use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorio "Dr. Fernando Cañas",Cátedra de Bioquímica y Biología Molecular, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
- INICSA (CONICET-Universidad Nacional de Córdoba), Córdoba, Argentina.
ORCID-Profile: Valeria A Rodríguez
Förderung
- FONCYT
- SECYT-UNC (VAR), Argentina
Zitieren
APA
Rizzi, M., Pérez, A., Guizzardi, S., Tolosa de Talamoni, N., & Rodríguez, V. A. (2025). Naringin prevents the impairment of hepatic mitochondrial function in diabetic rats. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2024-0357
Vancouver
Rizzi M, Pérez A, Guizzardi S, Tolosa de Talamoni N, Rodríguez VA. Naringin prevents the impairment of hepatic mitochondrial function in diabetic rats. Canadian Journal of Physiology and Pharmacology. 2025. doi:10.1139/cjpp-2024-0357
BibTeX
@article{Rizzi2025,
author = {Rizzi, María A and Pérez, Adriana and Guizzardi, Solange and Tolosa de Talamoni, Nori and Rodríguez, Valeria A},
title = {Naringin prevents the impairment of hepatic mitochondrial function in diabetic rats},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2025},
doi = {10.1139/cjpp-2024-0357}
}
EUVIMED